Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ADPT | CLUSTER | neutral | 3/10 | Two C-suite insiders at Adaptive Biotechnologies sold a combined $893K in open-market transactions within a 7-day window | Jun 8, 2026 |
| CING | CLUSTER | neutral | 3/10 | Five Cingulate insiders, including the CEO, CFO, and CMO, made open-market purchases totaling $44K over Feb 6-13, 2026. | Jun 8, 2026 |
| USNA | CLUSTER | neutral | 3/10 | Two insiders at USANA Health Sciences sold a combined $147K in open-market transactions over a one-week window, represen | Jun 8, 2026 |
| NBIX | CLUSTER | neutral | 4/10 | A cluster of insider selling at Neurocrine Biosciences, totaling ~$4.5M over a week, is dominated by C-suite officers ex | Jun 8, 2026 |
| ADTX | 3 | neutral | 4/10 | HRT Financial LP filed a Form 3 initial statement of beneficial ownership disclosing a 505,302 share stake in Aditxt, In | Jun 8, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of common stock, with a | Jun 8, 2026 |
| VXRT | DEFA14A | neutral | 4/10 | Vaxart has filed definitive additional proxy soliciting materials (DEFA14A) urging shareholders to vote FOR all six of t | Jun 8, 2026 |
| NOTV | 8-K | bearish | 9/10 | Inotiv filed for Chapter 11 bankruptcy on June 3, 2026, and entered into a $65.5M DIP credit facility on June 5, 2026. N | Jun 8, 2026 |
| MIRA | 8-K | neutral | 3/10 | Mira Pharmaceuticals disclosed the departure of CFO Alan Weichselbaum (effective June 6, 2026) and the appointment of An | Jun 8, 2026 |
| TELO | 8-K | neutral | 2/10 | Telomir Pharmaceuticals disclosed the departure of CFO Alan Weichselbaum and the appointment of Andriy Mushak as fractio | Jun 8, 2026 |
| ATYR | 8-K | bearish | 7/10 | aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025 for failing to maintain a minimum $1.00 bid price. O | Jun 8, 2026 |
| AVTX | 8-K | neutral | 3/10 | Avalo Therapeutics filed an 8-K reporting that stockholders approved the Second Amended and Restated 2016 Employee Stock | Jun 8, 2026 |
| ALVOW | 6-K | mixed | 6/10 | Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and a profit of $1.0M (d | Jun 8, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Four Liquidia Corp insiders, all directors and one CHRO, sold a total of $4.26M in open-market transactions over a 7-day | Jun 8, 2026 |
| JAGX | 8-K | neutral | 5/10 | Jaguar Health's 2026 Annual Meeting concluded on June 8, 2026 after two adjournments, with stockholders approving all fi | Jun 8, 2026 |
| JAZZ | DEFA14A | neutral | 3/10 | Jazz Pharmaceuticals filed a DEFA14A, which is additional definitive proxy soliciting material, filed as an amendment or | Jun 8, 2026 |
| KROS | CLUSTER | neutral | 2/10 | Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, following a round of non-cas | Jun 8, 2026 |
| LQDA | CLUSTER, 8-K | neutral | 5/10 | LQDA has been selected for addition to the S&P SmallCap 600 Index, effective prior to the opening of trading on June 22, | Jun 8, 2026 |
| BEIGF | 144 | neutral | 2/10 | Board member John Oyler filed a Form 144 to sell 4,940 ADSs (~$1.3M at the prevailing market price) from restricted stoc | Jun 8, 2026 |
| TNGX | 424B5 | bearish | 7/10 | Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $ | Jun 8, 2026 |
| IDYA | 424B5 | bearish | 6/10 | IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre- | Jun 8, 2026 |
| AUPH | INSIDER-BUY | bullish | 6/10 | Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bul | Jun 8, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two senior Teva executives, the CEO and an EVP, sold a combined $744K in open-market stock over a three-day window along | Jun 8, 2026 |
| IGC | 8-K | neutral | 3/10 | IGC Pharma extended its existing Master Loan and Security Agreement with O-Bank Co., Ltd., maintaining a $12,000,000 cre | Jun 8, 2026 |
| MTEX | 8-K | neutral | 2/10 | Mannatech appointed Yasir Haider as CFO, effective June 3, 2026, replacing James Clavijo. Haider had served as Interim C | Jun 8, 2026 |
| MTVA | 8-K | mixed | 6/10 | MetaVia Inc. held its 2026 annual meeting on June 8, 2026, with stockholders approving five proposals including the re-e | Jun 8, 2026 |
| EXOZ | 8-K | bearish | 7/10 | EXOZYMES INC. entered into an underwriting agreement on June 5, 2026, to sell 592,270 shares of common stock and 296,135 | Jun 8, 2026 |
| AGEN | COURT-RULING | bearish | 7/10 | Agenus Inc. and its CEO Garo Armen had their answers stricken and default judgment entered against them in a breach-of-c | Jun 8, 2026 |
| MEDP | COURT-RULING | bullish | 5/10 | Medpace, Inc. obtained a default judgment against Agenus Inc. and Garo H. Armen in a breach-of-contract and breach-of-fi | Jun 8, 2026 |
| SCNI | 6-K | neutral | 2/10 | Scinai filed a 6-K correcting a clerical error in its May 12 proxy statement regarding Chairman Mark Germain's service a | Jun 8, 2026 |